Posted by SalArmy4me on June 1, 2001, at 20:05:51
In reply to Topamax and Obesity, posted by Made-up Name on June 1, 2001, at 12:58:13
Author
Biton, V. MD et al
Neurology. 52(7):1330-1337, April 22, 1999:
Background and Objective: Topiramate is effective as adjunctive treatment of partial-onset seizures in adults. The efficacy and safety of topiramate as adjunctive therapy for the treatment of primary generalized tonic-clonic (PGTC) seizures were investigated in a randomized, double-blind, placebo-controlled study.Methods: Eighty patients, 3 to 59 years old, who experienced three or more PGTC seizures during an 8-week baseline phase were randomly assigned to treatment with either topiramate (n = 39) or placebo (n = 41). Topiramate was titrated to target doses of approximately 6 mg/kg/day over 8 weeks and maintained for another 12 weeks.
Results: The median percentage reduction from baseline in PGTC seizure rate was 56.7% for topiramate patients and 9.0% for placebo patients (p = 0.019). The proportion of patients with 50% or higher reduction in PGTC seizure rate was 22/39 (56%) and 8/40 (20%) for the topiramate and placebo groups, respectively (p = 0.001). The median percentage reduction in the rate of all generalized seizures was 42.1% for topiramate patients and 0.9% for placebo patients (p = 0.003). The proportions of patients with 50% or higher reductions in generalized seizure rate were 18/39 (46%) and 7/41 (17%) for the topiramate and placebo groups, respectively (p = 0.003). The most common adverse events were somnolence, fatigue, weight _loss_, difficulty with memory, and nervousness. Treatment-limiting adverse events occurred in one patient in the topiramate group (anorexia and weight loss) and one in the placebo group (granulocytopenia and thrombocytopenia).
Conclusion: Topiramate is well-tolerated and effective for the adjunctive treatment of PGTC seizures.Devlin, Michael J. M.D. et al. Obesity: What Mental Health Professionals Need to Know. American Journal of Psychiatry. 157(6):854-866, June 2000:
"Among mood stabilizers that have come into use more recently, gabapentin appears to be associated with weight gain in a substantial minority of patients, lamotrigine is not typically associated with weight change, and topiramate is associated with mild, dose-related weight loss."(also}
GORDON, ALAN MD et al. PRICE, LAWRENCE H. MD. Mood Stabilization and Weight Loss With Topiramate. American Journal of Psychiatry. 156(6):968-969, June 1999.
poster:SalArmy4me
thread:5053
URL: http://www.dr-bob.org/babble/20010530/msgs/65103.html